Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase II Preview For Roche's Dalcetrapib May Give CETP Inhibition A Boost

This article was originally published in The Pink Sheet Daily

Executive Summary

European Society of Cardiology Congress abstract for small study suggests Roche's dalcetrapib is safe and works on plaque burden.
Advertisement

Related Content

Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation
Simcere Teams Up Again With Bristol-Myers For Co-Development In China
Simcere Teams Up Again With Bristol-Myers For Co-Development In China
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit
Roche Exorcizes Torcetrapib’s Ghost: CETP Candidate Starts Phase III

Topics

Advertisement
UsernamePublicRestriction

Register

PS072681

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel